Country for PR: Hong Kong
Contributor: PR Newswire Asia (Hong Kong)
Wednesday, July 01 2020 - 09:00
Carmine Therapeutics and Takeda Collaborate to Discover and Develop Rare Disease Gene Therapies Using Novel Red Blood Cell Extracellular Vesicles Platform
CAMBRIDGE, Mass., July 1, 2020 /PRNewswire-AsiaNet/--

Takeda has also led Carmine's convertible note seed+ funding round by extending 
a $5M convertible loan to Carmine 

Carmine Therapeutics announced today that it has signed a research 
collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") 
to discover, develop and commercialize transformative non-viral gene therapies 
for two rare disease targets using Carmine's REGENT(TM) technology, based on 
red blood cell extracellular vesicles. In addition, Takeda has committed a $5M 
convertible loan in support of the development of Carmine's novel REGENT(TM) 

Logo -

Under the terms of the agreement, Carmine will receive an upfront payment, 
research funding support and is eligible for over $900M in total milestone 
payments plus tiered royalties. Takeda has an option to license the programs 
following the completion of pre-clinical proof of concept studies and would be 
responsible for clinical development and commercialization.

XQ Lin, Founding CEO of Carmine Therapeutics and Managing Partner of Esco 
Ventures, commented, "We are pleased to enter this collaboration with Takeda, a 
recognized global leader in rare disease therapies, slightly more than a year 
since Carmine was created and incubated by Esco Ventures X. This provides 
Carmine with significant funding to further develop our REGENT(TM) platform, 
and advance our wholly-owned programs."

Carmine Therapeutics is pioneering a novel class of therapeutics based on its 
REGENT(TM) technology which leverages red blood cell extracellular vesicles 
(RBCEVs), first published in Nature Communications in 2018. An initial focus is 
non-viral gene therapies. Compared to adeno-associated virus (AAV)-based gene 
therapy, RBCEV-based gene therapy has the potential for repeat dosing, a 
significantly larger transgene payload capacity in excess of 11KB, and enhanced 
bio-distribution in selected tissues through RBCEV surface modification.

"At Takeda, we're expanding our foundation in gene therapy by establishing a 
network of innovative partners like Carmine Therapeutics who are pursuing 
non-viral vector approaches that could leapfrog today's technology," said 
Takeda Rare Diseases Drug Discovery Unit Head Madhu Natarajan. "Developing 
alternative gene therapy delivery vehicles like the REGENT platform that could 
address the challenges of AAV gene therapy is critical to one day delivering 
next-generation cures for rare diseases."

About Carmine

Carmine Therapeutics was founded in 2019 by Esco Ventures X, Professor Harvey 
Lodish (Whitehead, MIT) and Singaporean Professors Minh Le and Jiahai Shi. 
Professor Lodish, who was a founding member of several successful biotech 
companies that include Genzyme, Arris (now Axys) Pharmaceuticals, Millennium 
Pharmaceuticals and Rubius Therapeutics, is also Chair of the Scientific 
Advisory Board of Carmine. Headquartered in Cambridge, MA with a research 
presence in Singapore, Carmine is pioneering a new class of therapeutics based 
on red blood cell extracellular vesicles. To date, Carmine has raised over 
$9.4M USD in seed equity financing led by Esco Ventures and Takeda Ventures. 
For more information, visit

About Esco Ventures X

Esco Ventures X, based in Cambridge, MA and Singapore, builds, incubates and 
invests in biotech companies, originating from platform technologies sourced 
globally. For more information, visit


Media Relations

Investor Relations 

Logo - 
Logo -

SOURCE  Carmine Therapeutics

Image Attachments Links:


   Caption: Esco Ventures X Logo


   Caption: Carmine Therapeutics Logo